Marshall Wace’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Marshall Wace’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,359	Closed	-$3.6M	–	2909
2023 Q4	$3.6M	Buy	+11,359	New	+$2.21M	0.01%	1027
2023 Q1	–	Sell	-1,207	Closed	-$237K	–	3294
2022 Q4	$237K	Sell	1,207 -60,905	-98%	-$13.1M	﹤0.01%	2647
2022 Q3	$14M	Buy	62,112 +11,531	+23%	+$2.33M	0.03%	639
2022 Q2	$6.4M	Buy	50,581 +42,821	+552%	+$4.92M	0.01%	1176
2022 Q1	$983K	Buy	7,760 +4,560	+143%	+$513K	﹤0.01%	2462
2021 Q4	$419K	Buy	+3,200	New	+$414K	﹤0.01%	2890
2021 Q2	–	Sell	-45,861	Closed	-$5.51M	–	3230
2021 Q1	$5.51M	Buy	+45,861	New	+$5.2M	0.03%	776
2020 Q2	–	Sell	-1,034	Closed	-$74K	–	2039
2020 Q1	$74K	Buy	+1,034	New	+$88.4K	﹤0.01%	1369

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Marshall Wace's KRTX Position: Q1 2024 in Review

Marshall Wace sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 11,359 shares — an estimated $3.6M sold.

Marshall Wace first reported a position in KRTX in Q1 2020 and held it in 8 quarters. The position peaked at $14M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Marshall Wace reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Marshall Wace sold 11,359 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.6M.
Marshall Wace first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2020 and held it in 8 quarters.
Marshall Wace's Karuna Therapeutics, Inc. Common Stock position peaked at $14M in Q3 2022.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Marshall Wace's 13F filing for Q1 2024, filed 15 May 2024.